These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C; Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038 [TBL] [Abstract][Full Text] [Related]
14. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Shihab F; Christians U; Smith L; Wellen JR; Kaplan B Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504 [TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. Rostaing L; Christiaans MH; Kovarik JM; Pascual J Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487 [TBL] [Abstract][Full Text] [Related]